Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis

被引:71
作者
Hadsell, DL
Murphy, KL
Bonnette, SG
Reece, N
Laucirica, R
Rosen, JM
机构
[1] Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
关键词
transgenic mouse model; IGF-I; apoptosis; mutant p53; tumorigenesis;
D O I
10.1038/sj.onc.1203386
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53(172R-H)). Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES, By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas. A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice, Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2-3-fold greater than that of nontransgenic and p53(172R-H) females, Tumor latency, however, was reduced by 8 months in bitransgenic mice as compared to mice of the other three genotypes. Aneuploidy was frequently observed in tumors from bitransgenic and p53(172R-H) mice, but not from mice expressing only the WAP-DES transgene, Expression of IGFBP3 was elevated in tumors from WAP-DES, but not bitransgenic mice, indicating an alteration in the p53/IGF-I axis. These studies indicate that overexpression of des(1-3)hIGF-I increases the frequency of MIN and stochastic mammary tumors and that the appearance of tumors displaying genomic instability is accelerated by mutant p53(172R-H).
引用
收藏
页码:889 / 898
页数:10
相关论文
共 50 条
[11]  
CULLEN KJ, 1990, CANCER RES, V50, P48
[12]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[13]  
DUNN TB, 1959, PHYSIOPATHOLOGY CANC, P38
[14]   Abnormal centrosome amplification in the absence of p53 [J].
Fukasawa, K ;
Choi, T ;
Kuriyama, R ;
Rulong, S ;
VandeVoude, GF .
SCIENCE, 1996, 271 (5256) :1744-1747
[15]  
Gai X X, 1988, Oncogene Res, V3, P377
[16]   Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner [J].
Gill, ZP ;
Perks, CM ;
Newcomb, PV ;
Holly, JMP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (41) :25602-25607
[17]   An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control [J].
Gualberto, A ;
Aldape, K ;
Kozakiewicz, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5166-5171
[18]  
HACHIYA M, 1994, ANTICANCER RES, V14, P1853
[19]   Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-Binding protein expression [J].
Hadsell, DL ;
Greenberg, NM ;
Fligger, JM ;
Baumrucker, CR ;
Rosen, JM .
ENDOCRINOLOGY, 1996, 137 (01) :321-330
[20]   Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects [J].
Hainaut, P ;
Soussi, T ;
Shomer, B ;
Hollstein, M ;
Greenblatt, M ;
Hovig, E ;
Harris, CC ;
Montesano, R .
NUCLEIC ACIDS RESEARCH, 1997, 25 (01) :151-157